Loading...

Matthew Everly

Title(s)Associate Adjunct Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
Phone310-267-1330
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection. Transplantation. 2020 Apr; 104(4):856-863. Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, Huang E, Jordan SC, Toyoda M. PMID: 31385933.
      View in: PubMed   Mentions: 1     Fields:    
    2. Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials. Am J Transplant. 2020 06; 20(6):1650-1658. Purnajo I, Beaumont JL, Polinsky M, Alemao E, Everly MJ. PMID: 31874117.
      View in: PubMed   Mentions:    Fields:    
    3. Pediatric intestinal transplantation: Analysis of the intestinal transplant registry. Pediatr Transplant. 2019 12; 23(8):e13580. Raghu VK, Beaumont JL, Everly MJ, Venick RS, Lacaille F, Mazariegos GV. PMID: 31531934.
      View in: PubMed   Mentions:    Fields:    
    4. Antibiotic pretreatment alleviates liver transplant damage in mice and humans. J Clin Invest. 2019 07 22; 129(8):3420-3434. Nakamura K, Kageyama S, Ito T, Hirao H, Kadono K, Aziz A, Dery KJ, Everly MJ, Taura K, Uemoto S, Farmer DG, Kaldas FM, Busuttil RW, Kupiec-Weglinski JW. PMID: 31329160.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    5. Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study. Transpl Int. 2019 May; 32(5):502-515. Schinstock CA, Dadhania DM, Everly MJ, Smith B, Gandhi M, Farkash E, Sharma VK, Samaniego-Picota M, Stegall MD. PMID: 30597643.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019 03; 69(3):1273-1286. Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. PMID: 30229989.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. Am J Transplant. 2019 03; 19(3):625-632. Stegall MD, Troy Somerville K, Everly MJ, Mannon RB, Gaber AO, First MR, Agashivala N, Perez V, Newell KA, Morris RE, Sudan D, Romero K, Eremenco S, Mattera M, Spear N, Porter AC, O'Doherty I. PMID: 30549395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant. 2019 06; 19(6):1671-1683. Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, Stegall MD. PMID: 30412654.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts. Am J Transplant. 2018 09; 18(9):2305-2313. Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM. PMID: 29767445.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    10. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct. 2018 Jun; 4(6):e353. Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. PMID: 30123826.
      View in: PubMed   Mentions:
    11. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation. 2017 09; 101(9):2062-2070. O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. PMID: 28452922.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss. J Immunol. 2017 06 01; 198(11):4524-4538. Ravindranath MH, Jucaud V, Banuelos N, Everly MJ, Cai J, Nguyen A, Terasaki PI. PMID: 28476933.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients. Transplantation. 2017 04; 101(4):873-882. Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS, Marcus EA, McDiarmid SV, Busuttil RW, Terasaki PI, Farmer DG. PMID: 27490417.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Transpl Int. 2017 Jun; 30(6):566-578. Everly MJ, Briley KP, Haisch CE, Dieplinger G, Bolin P, Kendrick SA, Morgan C, Maldonado AQ, Rebellato LM. PMID: 28211192.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. Am J Transplant. 2017 Jun; 17(6):1574-1584. Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, Cornell L, Stegall MD. PMID: 27977905.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    16. The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection. J Immunol Res. 2017; 2017:4072364. Hamdorf M, Kawakita S, Everly M. PMID: 28191475.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    17. HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. Transplantation. 2016 Nov; 100(11):2453-2460. Hussain SK, Makgoeng SB, Everly MJ, Goodman MT, Martínez-Maza O, Morton LM, Clarke CA, Lynch CF, Snyder J, Israni A, Kasiske BL, Engels EA. PMID: 26636741.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Incidence and impact of anti-HLA-DP antibodies in renal transplantation. Clin Transplant. 2016 09; 30(9):1108-14. Hörmann M, Dieplinger G, Rebellato LM, Briley KP, Bolin P, Morgan C, Haisch CE, Everly MJ. PMID: 27327607.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrol Dial Transplant. 2016 08; 31(8):1351-9. Lachmann N, Schönemann C, El-Awar N, Everly M, Budde K, Terasaki PI, Waiser J. PMID: 27190369.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    20. Donor-Specific HLA Antibodies: A Review of Data Published in 2016. Clin Transpl. 2016; 32:13-22. Idica A, Everly MJ. PMID: 28564519.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Cytokines as Biomarkers for Renal Transplant Recipients: What is New? Clin Transpl. 2016; 32:23-30. Kawakita S, Everly MJ. PMID: 28564520.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction. Transpl Infect Dis. 2015 Dec; 17(6):848-58. Dieplinger G, Everly MJ, Briley KP, Haisch CE, Bolin P, Maldonado AQ, Kendrick WT, Kendrick SA, Morgan C, Terasaki PI, Rebellato LM. PMID: 26442607.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    23. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection. Exp Mol Pathol. 2016 Feb; 100(1):45-50. Cai J, Terasaki PI, Zhu D, Lachmann N, Schönemann C, Everly MJ, Qing X. PMID: 26615783.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Management of patients with a failed kidney transplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy. World J Nephrol. 2015 May 06; 4(2):148-59. Pham PT, Everly M, Faravardeh A, Pham PC. PMID: 25949929.
      View in: PubMed   Mentions:
    25. Alloantibodies in Organ Transplant: A Review of Data Published in 2015. Clin Transpl. 2015; 31:139-146. Maehara C, Everly MJ. PMID: 28514575.
      View in: PubMed   Mentions:    Fields:    
    26. An Update on Cardiac Transplantation in the United States Based on an Analysis of the UNOS Registry. Clin Transpl. 2015; 31:27-34. Khatiwala JR, Everly MJ. PMID: 28514565.
      View in: PubMed   Mentions: 2     Fields:    
    27. There is a Road, No Simple Highway: Envisioning a Path to Better Long-Term Organ Transplant Survival. Clin Transpl. 2015; 31:203-209. Everly MJ. PMID: 28514582.
      View in: PubMed   Mentions:    Fields:    
    28. Risk Stratification of Human Leukocyte Antigen Class II Donor Specific Antibody Positive Patients by Immunoglobulin G Subclasses. Clin Transpl. 2015; 31:293-301. Taniguchi M, Rebellato LM, Briley KP, Haisch CE, Bolin P, Banuelos N, Hopfield J, Terasaki PI, Everly MJ. PMID: 28514591.
      View in: PubMed   Mentions: 2     Fields:    
    29. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction. Transplantation. 2014 Nov 27; 98(10):1097-104. Dieplinger G, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI. PMID: 24911039.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int. 2014 Dec; 27(12):1235-43. Bentall A, Tyan DB, Sequeira F, Everly MJ, Gandhi MJ, Cornell LD, Li H, Henderson NA, Raghavaiah S, Winters JL, Dean PG, Stegall MD. PMID: 24990476.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    31. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation. 2014 Mar 15; 97(5):494-501. Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Maldonado AQ, Harland RC, Terasaki PI. PMID: 24487396.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    32. The UNOS Renal Transplant Registry: Review of the Last Decade. Clin Transpl. 2014; 1-12. Andre M, Huang E, Everly M, Bunnapradist S. PMID: 26281122.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    33. Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry. Clin Transpl. 2014; 13-26. Cheng EY, Everly MJ. PMID: 26281123.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine. Clin Transpl. 2014; 33-47. Cai J, Wu G, Qing A, Everly M, Cheng E, Terasaki P. PMID: 26281125.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation. Clin Transpl. 2014; 137-42. Rebellato LM, Parker K, Everly MJ, Briley KP, Kendrick W, Kendrick S, Haisch CE, Terasaki PI, Bolin P. PMID: 26281138.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Update on Alloantibodies in Solid Organ Transplantation. Clin Transpl. 2014; 125-9. Everly MJ. PMID: 26281136.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Impact of the presence and duration of donor-specific antibodies on renal function. Transplant Proc. 2014 Jan-Feb; 46(1):75-80. Hoshino J, Everly MJ, Kaneku H, Ubara Y, Takaichi K, Terasaki PI. PMID: 24507029.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. An Update on Cardiac Transplantation in the United States. Clin Transpl. 2014; 27-32. Everly MJ. PMID: 26281124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearance. Transplantation. 2013 Nov 27; 96(10):919-25. Wu P, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI. PMID: 23912173.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clin Biochem. 2013 Oct; 46(15):1389-93. Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J. PMID: 23726814.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    41. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013 May 15; 95(9):1113-9. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. PMID: 23514959.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    42. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol. 2013 Mar; 24(4):655-64. Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Li L, Sigdel TK, Hsieh SC, Dai H, Naesens M, Waskerwitz J, Salvatierra O, Terasaki PI, Sarwal MM. PMID: 23449533.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    43. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 Feb 15; 95(3):410-7. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. PMID: 23380861.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    44. Novel biomarker combination predicts long-term allograft outcome. Clin Transpl. 2013; 319-24. Cail J, Huang W, Terasaki PI, Everly MJ, Briley KP, Haisch CE, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Rebellato LM. PMID: 25095524.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Understanding trends and predictors of outcome in elderly renal transplant recipients: an analysis of the UNOS registry. Clin Transpl. 2013; 1-11. Dieplinger G, Everly MJ. PMID: 25095487.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Donor risk factors in orthotopic liver transplant: analysis of the OPTN/UNOS registry. Clin Transpl. 2013; 13-22. Kawakita S, Everly MJ. PMID: 25095488.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Heart transplantation in an aging society: an analysis of 25 years of the OPTN/UNOS registry. Clin Transpl. 2013; 31-44. Hörmann M, Everly MJ. PMID: 25095490.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Incidence and hazards of alloantibodies in renal transplantation. Clin Transpl. 2013; 313-7. Everly MJ. PMID: 25095523.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013 May; 62(5):1656-64. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI. PMID: 23274902.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    50. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation. 2012 Jun 15; 93(11):1173-8. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. PMID: 22592887.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    51. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation. 2012 Mar 27; 93(6):572-7. Everly MJ, Terasaki PI, Trivedi HL. PMID: 22262128.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    52. Immunosuppression regimens to address alloantibodies in transplant recipients. Clin Transpl. 2012; 219-23. Everly MJ. PMID: 23721025.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Understanding and addressing the humoral immune response in transplant recipients. Clin Transpl. 2012; 225-7. Everly MJ. PMID: 23721026.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Deceased donor kidney transplantation in the United States from 1988 to 2011: an analysis of the OPTN/UNOS registry. Clin Transpl. 2012; 1-12. Zhu D, Everly MJ. PMID: 23721006.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Clin Transpl. 2012; 229-35. Kannabhiran D, Everly MJ, Walker-McDermott JK, Tiongko S, Friedlander R, Putheti P, Sharma V, Dadhania D. PMID: 23721027.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. The state of therapy for removal of alloantibody producing plasma cells in transplantation. Semin Immunol. 2012 Apr; 24(2):143-7. Everly MJ, Terasaki PI. PMID: 22153981.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    57. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011 Dec; 30(12):1320-6. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. PMID: 21968130.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    58. Role of proteasome inhibition in sensitized transplant candidates. Chin Med J (Engl). 2011 Mar; 124(5):771-4. Everly MJ, Everly JJ, Terasaki PI. PMID: 21518574.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients. Clin Transpl. 2011; 319-25. Everly MJ. PMID: 22755425.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients. Clin Transpl. 2011; 333-6. Everly MJ. PMID: 22755427.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients. Clin Transpl. 2011; 365-8. Wu P, Everly MJ, Jin J, Mao Y, Chen J. PMID: 22755432.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation. 2010 Dec 27; 90(12):1493-8. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, Kaneku H. PMID: 21042236.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    63. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation. 2010 Jul 27; 90(2):221-2. Trivedi HL, Terasaki PI, Feroz A, Vanikar AV, Trivedi VB, Khemchandani SI, Dave SD, Shankar V, Modi PR, Kaneku H, Idica A, Everly MJ. PMID: 20644455.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    64. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation. 2010 Apr 27; 89(8):962-7. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI. PMID: 20075791.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    65. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival. Clin Transpl. 2010; 317-22. Everly MJ. PMID: 21696049.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers. Clin Transpl. 2010; 353-62. Everly MJ. PMID: 21696053.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    67. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009 Aug 27; 88(4):568-74. Lee PC, Zhu L, Terasaki PI, Everly MJ. PMID: 19696641.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    68. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009 May 27; 87(10):1555-61. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. PMID: 19461494.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    69. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol. 2009 Aug; 70(8):655-9. Everly MJ, Terasaki PI. PMID: 19375466.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    70. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant. 2009 May; 9(5):1063-71. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES. PMID: 19344434.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    71. Heart transplantation in the United States from 1998 to 2008. Clin Transpl. 2009; 65-74. Ravindranath MH, Everly MJ. PMID: 20524277.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Clonal deletion using total lymphoid irradiation with no maintenance immunosuppression in renal allograft recipients. Clin Transpl. 2009; 265-80. Trivedi HL, Kaneku H, Terasaki PI, Feroz A, Vanikar AV, Trivedi VB, Khemchandani SI, Dave SD, Modi PR, Jahr F, Idica A, Everly MJ. PMID: 20524291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol. Clin Transpl. 2009; 281-93. Everly MJ, Jahr F, Kaneku H, Trivedi HL, Terasaki PI. PMID: 20524292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    74. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl. 2009; 323-37. Everly MJ. PMID: 20524294.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    75. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report. Clin Transpl. 2009; 347-9. Patel JK, Everly MJ, Kittleson M, Kobashigawa JA. PMID: 20524297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc. 2009 Jan-Feb; 41(1):105-7. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES. PMID: 19249489.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    77. Pancreas transplantation in the United States: an analysis of the UNOS registry. Clin Transpl. 2009; 75-81. Everly MJ. PMID: 20527068.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008 Dec 27; 86(12):1754-61. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. PMID: 19104417.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    79. Donor-specific HLA antibody response in clonal deletion. Clin Transpl. 2008; 189-98. Kaneku H, Idica A, Everly MJ, Terasaki PI, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Trivedi HL. PMID: 19708456.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl. 2008; 229-39. Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI. PMID: 19708459.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    81. Cardiac transplantation in the United States: an analysis of the UNOS registry. Clin Transpl. 2008; 35-43. Everly MJ. PMID: 19708444.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    82. Detailed examination of HLA antibody development on renal allograft failure and function. Clin Transpl. 2008; 171-87. Zhu L, Lee PC, Everly MJ, Terasaki PI. PMID: 19711514.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    83. Posttransplant lymphoproliferative disorder. Ann Pharmacother. 2007 Nov; 41(11):1850-8. Everly MJ, Bloom RD, Tsai DE, Trofe J. PMID: 17940127.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    84. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004 Feb; 38(2):286-93. Everly MJ, Heaton PC, Cluxton RJ. PMID: 14742768.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    Matthew's Networks
    Concepts (221)
    Derived automatically from this person's publications.
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _